Just - Evotec Biologics

Evotec SE announce the signing of a non-binding agreement with Sandoz AG regarding the potential sale of Just - Evotec Biologics EU, which owns the J.POD biologics manufacturing facility in Toulouse, France, and to grant access to its proprietary platform for integrated development and advanced continuous manufacturing of biologics via a technology license. Read the full press release here: https://lnkd.in/eXRDnqVF

If you missed our recent joint webinar with Protein Metrics on MS Glycan Analysis, it is now available on-demand. Kiran Iyer, Senior Scientist, Process and Product Design, discussed 𝗵𝗼𝘄 𝗮𝗱𝘃𝗮𝗻𝗰𝗲𝗱 𝗠𝗦 𝘄𝗼𝗿𝗸𝗳𝗹𝗼𝘄𝘀 𝗮𝗻𝗱 𝗴𝗹𝘆𝗰𝗮𝗻 𝗴𝗿𝗼𝘂𝗽𝗶𝗻𝗴 𝗶𝗺𝗽𝗿𝗼𝘃𝗲 𝗯𝗶𝗼𝘁𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰 𝗮𝗻𝗮𝗹𝘆𝘀𝗶𝘀, 𝗳𝗿𝗼𝗺 𝗿𝗮𝘄 𝗱𝗮𝘁𝗮 𝘁𝗼 𝗺𝗲𝗮𝗻𝗶𝗻𝗴𝗳𝘂𝗹 𝗶𝗻𝘀𝗶𝗴𝗵𝘁. Watch it here: https://hubs.ly/Q03x_P2V0 #Antibody #Glycans #Glycosylation #MassSpec

Join us for the annual Cascadia Proteomics Symposium at the Institute for Systems Biology in #Seattle, July 17-18. The event brings #proteomics researchers from the Pacific Northwest region, Washington, Oregon, and British Columbia, to discuss great science, get to know each other better, share ideas, and foster collaboration within the region. Just – Evotec Biologics will participate with two presentations: A Comprehensive Characterization Method for Cysteine-related Product Quality Attributes in Antibody-based Therapeutics   • Theresa Gozzo-Southward, Scientist I in Mass Spectrometry   • Thursday, July 17 @ 15:35 PT DOE-Based Comparative Analysis of MAM on Thermo Fisher Q Exactive™ HF and Exploris™ 240 for Therapeutic Antibodies   • Jianji Chen, Scientist II in Mass Spectrometry   • Friday, July 18 @ 11:30 PT We look forward to seeing you there! https://hubs.ly/Q03x0F1k0 #MassSpec #Biologics #Antibodies

If you missed us at the recent #ASMS conference, you will find our poster “𝗔 𝗖𝗼𝗺𝗽𝗿𝗲𝗵𝗲𝗻𝘀𝗶𝘃𝗲 𝗖𝗵𝗮𝗿𝗮𝗰𝘁𝗲𝗿𝗶𝘇𝗮𝘁𝗶𝗼𝗻 𝗠𝗲𝘁𝗵𝗼𝗱 𝗳𝗼𝗿 𝗖𝘆𝘀𝘁𝗲𝗶𝗻𝗲-𝗿𝗲𝗹𝗮𝘁𝗲𝗱 𝗣𝗿𝗼𝗱𝘂𝗰𝘁 𝗤𝘂𝗮𝗹𝗶𝘁𝘆 𝗔𝘁𝘁𝗿𝗶𝗯𝘂𝘁𝗲𝘀 𝗶𝗻 𝗔𝗻𝘁𝗶𝗯𝗼𝗱𝘆-𝗕𝗮𝘀𝗲𝗱 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀” available for download on our website. About the poster: Disulfide bonds are critical in stabilizing the three-dimensional structures of antibody-based therapeutics. Free and improperly paired cysteines can lead to aggregation or immunogenicity. Other cysteine modifications, like glutathionylation, cysteinylation, or trisulfide and thioether bond formation can be considered product-related impurities, so it is essential to accurately characterize cysteines in biopharmaceuticals. Often, a bottom-up mass spectrometry approach is taken to localize disulfides and cysteine modifications; however, conditions like alkaline pH and high temperatures can lead to method-induced disulfide artifacts that complicate these analyses. Various methods have been proposed to minimize artifacts, but they only focus on the analysis of a subset of cysteine modifications, most often native and scrambled disulfide bonds. We present a cysteine characterization method that provides a more comprehensive analysis. Learn more here: https://hubs.ly/Q03v_Rlm0 #Antibody #MassSpec #MassSpectrometry #Cysteine

It was a pleasure to attend and speak at the recent Sartorius Process Intensification Forum in Boston. At Just – Evotec Biologics we are convinced that continuous manufacturing of #biologics is the way forward! We have developed an integrated, continuous biomanufacturing platform that combines a #perfusion cell culture step with a fully connected and intensified downstream process. We can manufacture drug substance with hybrid (‘semi-continuous’) or fully continuous (‘end-to-end’) modes of operation using either 500 L or 1000 L scale single-use bioreactors depending on the amount of drug substance needed. We see significant 𝗯𝗲𝗻𝗲𝗳𝗶𝘁𝘀 𝗼𝗳 𝘂𝘀𝗶𝗻𝗴 𝗽𝗲𝗿𝗳𝘂𝘀𝗶𝗼𝗻 compared to traditional fed-batch: 1. 𝗛𝗶𝗴𝗵𝗲𝗿 𝗰𝗲𝗹𝗹 𝗱𝗲𝗻𝘀𝗶𝘁𝗶𝗲𝘀: Perfusion allows for continuous cell growth, leading to higher cell densities compared to batch or fed-batch processes. This results in increased productivity. 2. 𝗦𝘁𝗮𝗯𝗹𝗲 𝗽𝗿𝗼𝗱𝘂𝗰𝘁 𝗾𝘂𝗮𝗹𝗶𝘁𝘆: The consistent environment in perfusion culture helps support consistent product quality over extended periods. This is crucial for biopharmaceuticals like monoclonal antibodies. 3. 𝗥𝗲𝗱𝘂𝗰𝗲𝗱 𝗳𝗼𝗼𝘁𝗽𝗿𝗶𝗻𝘁: Perfusion systems can achieve the same production yield with smaller bioreactors, allowing patient demand to be met in smaller manufacturing facilities. 4. 𝗟𝗼𝗻𝗴𝗲𝗿 𝗽𝗿𝗼𝗱𝘂𝗰𝘁𝗶𝗼𝗻 𝗿𝘂𝗻𝘀: Perfusion enables continuous operation, reducing downtime and improving overall facility throughput. 5. 𝗙𝗹𝗲𝘅𝗶𝗯𝗶𝗹𝗶𝘁𝘆: Output from perfusion processes can be ramped up without significant changes of scale, making them suitable for production from early clinical supply through to commercial manufacturing. 6. 𝗜𝗺𝗽𝗿𝗼𝘃𝗲𝗱 𝗽𝗿𝗼𝗰𝗲𝘀𝘀 𝗲𝗰𝗼𝗻𝗼𝗺𝗶𝗰𝘀: Perfusion upstream processes reduce the manufacturing costs of biopharmaceuticals when integrated with a connected continuous downstream process. Learn more about perfusion here: https://lnkd.in/d5YsTVTW #PIForum2025 #biomanufacturing #bioprocessing

It was a pleasure hosting the Secretary General for Investment (SGPI), Mr. Bruno BONNELL, here in #Toulouse as part of his tour of the France 2030 plan awardees. As Just – Evotec Biologics we are very proud to be part of the France 2030 plan with our J.POD® biomanufacturing facility in Toulouse. France 2030 is a strategic investment plan launched by the French government in October 2021, with a budget of 54 billion euros over 5 years. Its goal is to prepare France for the major challenges of the future by focusing on innovation, reindustrialization, ecological transition, and technological sovereignty. The SGPI, in turn, is responsible for managing and monitoring major public investments by the State, particularly those related to the France 2030 plan. #Biologics #France

Learn about the latest trends in #antibody discovery and development in this latest eBook by Drug Discovery World (DDW)! It discusses:   • The 2025 scientific breakthroughs in the field of mAbs   • How single-use technologies can improve antibody production   • Polyclonal and recombinant antibody development   • How to overcome the challenges of measuring antibody aggregation Download the eBook here: https://hubs.ly/Q03v8x3V0 #Biologics #Biotherapeutics #Biopharma

Missed our June newsletter? Not to worry, you can now read it directly on LinkedIn!

At the recent #ASMS conference, we presented a poster on “DOE-Based Comparative Analysis of MAM on Thermo Fisher Q Exactive™ HF and Exploris™ 240 for Therapeutic Antibodies”. If you were unable to attend, we have made the poster available on our website. About the research poster: The 𝗺𝘂𝗹𝘁𝗶-𝗮𝘁𝘁𝗿𝗶𝗯𝘂𝘁𝗲 𝗺𝗲𝘁𝗵𝗼𝗱 (𝗠𝗔𝗠) 𝗶𝘀 𝗶𝗻𝗰𝗿𝗲𝗮𝘀𝗶𝗻𝗴𝗹𝘆 𝗲𝗺𝗽𝗹𝗼𝘆𝗲𝗱 𝗶𝗻 𝘁𝗵𝗲 #𝗯𝗶𝗼𝗽𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹 𝗶𝗻𝗱𝘂𝘀𝘁𝗿𝘆 for comprehensive characterization of therapeutic #antibodies. Despite advancements in mass spectrometry instrumentation, systematic comparisons of performance across platforms remain scarce. This study evaluates two widely utilized instruments, Q Exactive and Exploris 240, focusing on their capability to identify and quantify post-translational modifications (PTMs) under a design of experiments (DOE) framework. 𝗢𝘂𝗿 𝗳𝗶𝗻𝗱𝗶𝗻𝗴𝘀 𝗮𝗱𝗱𝗿𝗲𝘀𝘀 𝗮 𝗰𝗿𝗶𝘁𝗶𝗰𝗮𝗹 𝗴𝗮𝗽 𝗶𝗻 𝗠𝗔𝗠 𝘄𝗼𝗿𝗸𝗳𝗹𝗼𝘄𝘀, particularly in understanding instrument-specific performance differences in cross-site or cross-instrument data comparisons. Learn more here: https://lnkd.in/dt_DEMRK #MAM #massspec #MassSpectrometry

Well done, Ron!